IL-6 activated STAT3-driven metastasis by co-opting ER-FOXA1-STAT3 enhancers metastasis, suggesting that targeting IL6/STAT3 may have clinical potential in ER+ breast cancer [35]. This evidence concerns the gene FOXA1 and breast carcinoma.